Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Unicycive Therapeutics (UNCY) Shares Outstanding (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Shares Outstanding readings, the most recent being $11.4 million for Q4 2024.

  • On a quarterly basis, Shares Outstanding rose 227.55% to $11.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $11.4 million, a 227.55% increase, with the full-year FY2024 number at $11.4 million, up 227.55% from a year prior.
  • Shares Outstanding hit $11.4 million in Q4 2024 for Unicycive Therapeutics, up from $9.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $34.8 million in Q3 2023 to a low of $43649.0 in Q4 2023.
  • Median Shares Outstanding over the past 4 years was $15.0 million (2022), compared with a mean of $13.1 million.
  • The widest YoY moves for Shares Outstanding: up 227.55% in 2024, down 99.89% in 2024.
  • Unicycive Therapeutics' Shares Outstanding stood at $15.0 million in 2021, then rose by 1.57% to $15.2 million in 2022, then plummeted by 77.18% to $3.5 million in 2023, then soared by 227.55% to $11.4 million in 2024.
  • The last three reported values for Shares Outstanding were $11.4 million (Q4 2024), $7882.0 (Q3 2024), and $17073.1 (Q2 2024) per Business Quant data.